Skip to content
sellWeak cluster of 210b5-1 plan

James Kihara sold $90k of ACAD

PRINCIPAL ACCOUNTING OFFICER at ACADIA PHARMACEUTICALS INC. 4,000 shares at an average of $22.50, traded May 16, 2025, filed May 19, 2025.

Warning score
17
Value
$90k
4,000 shares
Holdings after
20,395
-16% from before
From 52-week low
+58%
low $14.10, close $22.26
From 52-week high
0%
high $22.26, as of May 16, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $90k at market
    +9
  • Share of holdings sold
    Sold 16% of holdings
    +5
  • Cluster
    2 insiders selling within 14 days
    +8
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ACADOct 9, 2026 · close 19.78
Since filing May 19, 2025: -10.1%SPY +33.1% · excess -43.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001415889-25-013742, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
May 16, 2025SOpen-market sale
Common Stock10b5-1
-2,000$25.00$50k22,395May 19, 2025
May 16, 2025SOpen-market sale
Common Stock10b5-1
-2,000$20.00$40k20,395May 19, 2025

Related signals

Other insiders at ACADIA PHARMACEUTICALS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
19Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$83k
3,498 shares
-7%
29Weak
ACADsell 2
ACADIA PHARMACEUTICALS INC
Elizabeth A. Garofalo
director
$42k
1,600 shares
-6%
31Weak
ACADsell10b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$554k
22,000 shares
-35%
39Weak
ACADsell
ACADIA PHARMACEUTICALS INC
Laura Brege
director
$315k
14,446 shares
-49%
17Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$50k
2,000 shares
-3%
2Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$51k
3,498 shares
-5%
0Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
James Kihara
PRINCIPAL ACCOUNTING OFFICER
$19k
1,327 shares
-5%
0Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
James Kihara
PRINCIPAL ACCOUNTING OFFICER
$15k
1,028 shares
-4%
1Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$40k
2,708 shares
-4%
2Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$54k
3,171 shares
-5%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

James Kihara sold $90k of ACAD | InsiderTell